دورية أكاديمية
Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers After Coronary Artery Bypass Graft Surgery: A Population-Based Cohort Study.
العنوان: | Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers After Coronary Artery Bypass Graft Surgery: A Population-Based Cohort Study. |
---|---|
المؤلفون: | Barry AR; Faculty of Pharmaceutical Sciences The University of British Columbia Vancouver British Columbia Canada.; Jim Pattison Outpatient Care and Surgery Centre Lower Mainland Pharmacy Services Surrey British Columbia Canada., Helisaz H; GranTAZ Consulting Vancouver British Columbia Canada.; Faculty of Applied Science The University of British Columbia Vancouver British Columbia Canada., Safari A; GranTAZ Consulting Vancouver British Columbia Canada.; School of Mathematics, Statistics and Computer Science, College of Science University of Tehran Tehran Iran., Loewen P; Faculty of Pharmaceutical Sciences The University of British Columbia Vancouver British Columbia Canada.; Centre for Cardiovascular Innovation The University of British Columbia Vancouver British Columbia Canada.; Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences The University of British Columbia Vancouver British Columbia Canada. |
المصدر: | Journal of the American Heart Association [J Am Heart Assoc] 2024 Jun 18; Vol. 13 (12), pp. e035215. Date of Electronic Publication: 2024 Jun 06. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Oxford : Wiley-Blackwell |
مواضيع طبية MeSH: | Coronary Artery Bypass*/adverse effects , Angiotensin-Converting Enzyme Inhibitors*/therapeutic use , Angiotensin-Converting Enzyme Inhibitors*/adverse effects , Angiotensin Receptor Antagonists*/therapeutic use , Angiotensin Receptor Antagonists*/adverse effects, Humans ; Male ; Female ; Aged ; Retrospective Studies ; British Columbia/epidemiology ; Middle Aged ; Coronary Artery Disease/surgery ; Coronary Artery Disease/mortality ; Treatment Outcome ; Risk Factors ; Myocardial Infarction/epidemiology ; Time Factors ; Postoperative Complications/epidemiology |
مستخلص: | Background: The effect of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) on major adverse cardiovascular events (MACE) in patients who undergo coronary artery bypass graft surgery is equivocal. This retrospective, population-based cohort study evaluated effect of exposure to an ACEI/ARB on MACE using linked administrative databases that included all cardiac revascularization procedures, hospitalizations, and prescriptions for the population of British Columbia, Canada. Methods and Results: All adults who underwent coronary artery bypass graft surgery between 2002 and 2020 were eligible. The primary outcome was time to MACE, defined as a composite of all-cause death, myocardial infarction, and ischemic stroke using Cox proportional hazards models with inverse probability treatment weighting. Included were 15 439 patients and 6191 (40%) were prescribed an ACEI/ARB. Mean age was 66 years, 83% were men, and 16% had heart failure (HF). Median exposure time was 40 months. Over the 5-year follow-up, 1623 MACE occurred. Impact of exposure was different for patients with and without HF ( P <0.0001 for interaction). After probability-weighting and adjustment for relevant covariates, exposure to ACEI/ARBs was associated with a lower hazard of MACE in patients with HF at 1 year (hazard ratio, 0.13 [95% CI, 0.09-0.19]) and 5 years (hazard ratio, 0.36 [95% CI, 0.30-0.44]). In patients without HF, ACEI/ARBs had a lower hazard of MACE at 1 year (hazard ratio, 0.35 [95% CI, 0.27-0.46]) and 5 years (hazard ratio, 0.66 [95% CI, 0.58-0.76]). Conclusions: In this population-based study, ACEI/ARBs were associated with a lower hazard of MACE in a cohort of patients post-coronary artery bypass graft surgery irrespective of HF status. |
References: | Circulation. 2008 Jan 1;117(1):24-31. (PMID: 18071079) Eur Heart J. 1997 Jan;18(1):41-51. (PMID: 9049514) JAMA. 2002 Jul 24-31;288(4):455-61. (PMID: 12132975) J Card Surg. 2020 Jan;35(1):58-65. (PMID: 31782835) Br J Clin Pharmacol. 2022 Oct;88(10):4427-4442. (PMID: 35524398) PLoS One. 2015 Aug 20;10(8):e0135834. (PMID: 26292280) J Am Coll Cardiol. 2000 Mar 15;35(4):881-8. (PMID: 10732883) Am J Cardiol. 2001 Mar 1;87(5):542-6. (PMID: 11230836) Pharmacoepidemiol Drug Saf. 2020 Sep;29(9):1101-1110. (PMID: 32783283) JAMA. 2013 Nov 20;310(19):2086-95. (PMID: 24240936) Med Care. 2008 Nov;46(11):1125-33. (PMID: 18953222) Lancet. 2003 Sep 6;362(9386):772-6. (PMID: 13678870) BMC Med Res Methodol. 2021 Nov 6;21(1):241. (PMID: 34742250) Stroke. 2005 Aug;36(8):1776-81. (PMID: 16020772) J Am Coll Cardiol. 2006 Apr 18;47(8):1576-83. (PMID: 16630993) N Engl J Med. 1991 Aug 1;325(5):293-302. (PMID: 2057034) Eur Heart J. 2014 Oct 21;35(40):2821-30. (PMID: 24849105) Circulation. 2013 Jan 29;127(4):e362-425. (PMID: 23247304) N Engl J Med. 2001 Dec 6;345(23):1667-75. (PMID: 11759645) Ann Surg. 2023 Apr 1;277(4):e948-e954. (PMID: 35166263) CJC Open. 2019 Oct 19;1(6):297-304. (PMID: 32159124) Circulation. 2015 Mar 10;131(10):927-64. (PMID: 25679302) Pharmacotherapy. 2014 May;34(5):464-72. (PMID: 24877186) J Clin Epidemiol. 2008 Apr;61(4):344-9. (PMID: 18313558) Circulation. 2014 Dec 23;130(25):e344-426. (PMID: 25249585) Am Heart J. 2011 Nov;162(5):836-43. (PMID: 22093199) Health Serv Res. 2013 Feb;48(1):290-318. (PMID: 22742621) BMJ. 2018 Nov 14;363:k3532. (PMID: 30429167) Am J Manag Care. 2009 Jul;15(7):457-64. (PMID: 19589013) N Engl J Med. 2000 Jan 20;342(3):145-53. (PMID: 10639539) Eur Heart J. 2023 Oct 12;44(38):3720-3826. (PMID: 37622654) Circulation. 2022 Feb 22;145(8):e153-e639. (PMID: 35078371) |
فهرسة مساهمة: | Keywords: angiotensin receptor antagonists; angiotensin‐converting enzyme inhibitors; coronary artery bypass; coronary artery disease; medication adherence |
المشرفين على المادة: | 0 (Angiotensin-Converting Enzyme Inhibitors) 0 (Angiotensin Receptor Antagonists) |
تواريخ الأحداث: | Date Created: 20240606 Date Completed: 20240618 Latest Revision: 20240720 |
رمز التحديث: | 20240720 |
مُعرف محوري في PubMed: | PMC11255732 |
DOI: | 10.1161/JAHA.124.035215 |
PMID: | 38842283 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!